BroadOak Capital Partners advised Omixon on its sale of the company to Werfen. Omixon, a privately
BroadOak Capital Partners advised Omixon on its sale of the company to Werfen. Omixon, a privately
BroadOak Capital Partners invested in PAK Biosolutions to expand their commercial and product development. The full
BroadOak Capital Partners advised LabConnect on its acquisition of A4P Bio. A4P Bio provides bioanalytical project
BroadOak Capital Partners advised ZoBio on the sale of the company to Oncodesign Services. ZoBio is
BroadOak Capital Partners led Pluristyx’s latest fundraising round, which featured participation from existing investors and key
BroadOak Capital Partners advised Biosynth on the acquisition of celares GmbH. Celares provides customized bioconjugation solutions
Genomenon, a BroadOak portfolio company and a leader in genomic intelligence, acquired Boston Genetics, a genomics
BroadOak Capital Partners invested in Indee Labs out of its BioTools Venture Fund to support the
Sanguine is a leader in custom specimen procurement used by biopharmaceutical companies to accelerate precision medicine
It is an exciting time at BroadOak as we help advance innovative life sciences technologies.
Holly Atallah
Director of Finance & Operations
BroadOak has advised and invested in life sciences companies for over 15 years. Get to know us.
Stay connected
Partner with BroadOak